FDA to Issue Stricter Guidance for Emergency Authorization of COVID-19 Vaccine
By HospiMedica International staff writers Posted on 24 Sep 2020 |
Illustration
The US Food and Drug Administration (FDA Silver Spring, MD, USA) is reportedly planning to announce new tougher standards for an emergency authorization of a COVID-19 vaccine in an effort to boost transparency and public trust.
A report by The Washington Post states that the FDA’s guidance for emergency authorization of a COVID-19 vaccine would be much stricter compared to the one issued earlier for hydroxychloroquine or convalescent plasma. The new guidance is being reviewed by the White House Office of Management and Budget, and elements of it have already been shared with the vaccine makers. As per the guidance, the FDA could ask vaccine manufacturers seeking an emergency authorization to follow participants in late-stage clinical trials for a median of at least two months, beginning after they have been administered a second vaccine shot, according to The Washington Post report.
In order to ensure that the COVID-19 vaccine works, the FDA may look for a minimum of five severe cases of COVID-19 in the placebo groups of all the trials, as well as some cases in older people. These tougher standards, coupled with the time required for the vaccine makers to prepare their applications as well as for the FDA to review the data, make it highly unlikely for any COVID-19 vaccine to be authorized before the US presidential election.
“It’s hard to imagine how an (emergency use authorization) could possibly occur before December,” Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia and a member of the FDA’s advisory board on vaccines, told The Washington Post.
Related Links:
US Food and Drug Administration (FDA)
A report by The Washington Post states that the FDA’s guidance for emergency authorization of a COVID-19 vaccine would be much stricter compared to the one issued earlier for hydroxychloroquine or convalescent plasma. The new guidance is being reviewed by the White House Office of Management and Budget, and elements of it have already been shared with the vaccine makers. As per the guidance, the FDA could ask vaccine manufacturers seeking an emergency authorization to follow participants in late-stage clinical trials for a median of at least two months, beginning after they have been administered a second vaccine shot, according to The Washington Post report.
In order to ensure that the COVID-19 vaccine works, the FDA may look for a minimum of five severe cases of COVID-19 in the placebo groups of all the trials, as well as some cases in older people. These tougher standards, coupled with the time required for the vaccine makers to prepare their applications as well as for the FDA to review the data, make it highly unlikely for any COVID-19 vaccine to be authorized before the US presidential election.
“It’s hard to imagine how an (emergency use authorization) could possibly occur before December,” Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia and a member of the FDA’s advisory board on vaccines, told The Washington Post.
Related Links:
US Food and Drug Administration (FDA)
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans